JPH1067662A5 - - Google Patents

Info

Publication number
JPH1067662A5
JPH1067662A5 JP1997204345A JP20434597A JPH1067662A5 JP H1067662 A5 JPH1067662 A5 JP H1067662A5 JP 1997204345 A JP1997204345 A JP 1997204345A JP 20434597 A JP20434597 A JP 20434597A JP H1067662 A5 JPH1067662 A5 JP H1067662A5
Authority
JP
Japan
Prior art keywords
formula
alkyl
group
hydrogen atom
integer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1997204345A
Other languages
English (en)
Japanese (ja)
Other versions
JPH1067662A (ja
Filing date
Publication date
Priority claimed from DE19640556A external-priority patent/DE19640556A1/de
Application filed filed Critical
Publication of JPH1067662A publication Critical patent/JPH1067662A/ja
Publication of JPH1067662A5 publication Critical patent/JPH1067662A5/ja
Ceased legal-status Critical Current

Links

JP9204345A 1996-07-31 1997-07-30 アポプトーシスのモジュレーションのためのキサンチン誘導体の使用 Ceased JPH1067662A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19630837 1996-07-31
DE19640556A DE19640556A1 (de) 1996-10-01 1996-10-01 Verwendung von Xanthinderivaten zur Modulation der Apoptose
DE19630837:2 1996-10-01
DE19640556:4 1996-10-01

Publications (2)

Publication Number Publication Date
JPH1067662A JPH1067662A (ja) 1998-03-10
JPH1067662A5 true JPH1067662A5 (enExample) 2005-05-19

Family

ID=26027961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9204345A Ceased JPH1067662A (ja) 1996-07-31 1997-07-30 アポプトーシスのモジュレーションのためのキサンチン誘導体の使用

Country Status (11)

Country Link
US (1) US5856330A (enExample)
EP (1) EP0821960B1 (enExample)
JP (1) JPH1067662A (enExample)
AT (1) ATE236637T1 (enExample)
AU (1) AU718237B2 (enExample)
CA (1) CA2212205C (enExample)
DE (1) DE59709755D1 (enExample)
DK (1) DK0821960T3 (enExample)
ES (1) ES2191794T3 (enExample)
MX (1) MX9705771A (enExample)
PT (1) PT821960E (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011051A (en) * 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
DE19860802A1 (de) * 1998-12-30 2000-10-26 Virgene Pharmaceuticals Ag Herstellung eines Mittels gegen Hepatitis B-, HI-, Paramyxo und Orthomyxo-Viren
US6458930B1 (en) 2000-11-28 2002-10-01 Cytokinetics, Inc. Aspergillus fumigatus cofilin
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
FR2825928B1 (fr) * 2001-06-18 2004-04-02 Ecole Norm Superieure Cachan Composition pharmaceutique pour le diagnostic, la prevention ou le traitement d'une pathologie tumorale, comprenant un agent modulateur de l'etat polymerisation de l'actine
ATE423567T1 (de) 2001-12-28 2009-03-15 Asubio Pharma Co Ltd Cofilin zur förderung der proliferation und/oder differenzierung hämatopoetischer stammzellen und/oder hämatopoetischer vorläuferzellen
DE10217254A1 (de) * 2002-04-15 2003-10-23 Proteosys Ag Verwendung von Substanzen zur Behandlung von Tumoren
GB0224014D0 (en) * 2002-10-15 2002-11-27 Oxford Glycosciences Uk Ltd A protein involved in therapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3737433A (en) * 1964-09-05 1973-06-05 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines
DE2335170C2 (de) * 1973-07-11 1989-07-20 Hoechst Ag, 6230 Frankfurt 1,3-Dialkyl-7-(hydroxyalkyl)-xanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
NL186239B (nl) * 1975-06-05 Hoechst Ag Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze.
DE3508097A1 (de) * 1984-07-21 1986-02-06 Hoechst Ag, 6230 Frankfurt Kombinationspraeparat aus xanthinderivaten und o-acetylsalicylsaeure bzw. deren pharmakologisch vertraeglichen salzen und dessen verwendung
DE3525801A1 (de) * 1985-07-19 1987-01-22 Hoechst Ag Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung
IL106861A (en) * 1986-12-31 1997-02-18 Hoechst Roussel Pharma Pentoxifylline metabolites and pharmaceutical formulations containing them for inhibiting the activity of interleukin-1 and leukocyte-derived cytokines
IL99811A (en) * 1990-10-30 1996-03-31 Roussel Uclaf 3-cycloalkyl-propanamides their tautomer forms and their salts preparation process and compositions containing them
AU9084991A (en) * 1990-11-01 1992-05-26 Board Of Regents, The University Of Texas System Antifungal activity of and prevention of drug induced nephrotoxicity by methylxanthine analogues
ES2093138T3 (es) * 1991-05-23 1996-12-16 Hoechst Ag El empleo de 1-(5-oxohexil)-3-metil-7-n-propil-xantina en cirugia vascular.
CA2109796C (en) * 1991-05-24 2004-04-27 James A. Bianco Modulation of cellular response to external stimuli
MX9203323A (es) * 1991-07-11 1994-07-29 Hoechst Ag El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales.
TW209834B (enExample) * 1991-12-11 1993-07-21 Hoechst Ag
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
DE59304710D1 (de) * 1992-02-22 1997-01-23 Hoechst Ag Verwendung von Xanthinderivaten zur Behandlung von Muskelschädigungen nach vollständiger Unterbrechung der Blutzirkulation
US5763446A (en) * 1992-03-26 1998-06-09 University Of Southern California Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases
GB9321083D0 (en) * 1993-10-13 1993-12-01 Univ Mcgill Phosphatase inhibitors in channel diseases
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
WO1996005836A2 (en) * 1994-08-25 1996-02-29 Medical University Of South Carolina Methods of treating cold symptoms using pentoxifylline
CA2208580A1 (en) * 1994-12-29 1996-07-11 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction

Similar Documents

Publication Publication Date Title
KR101388087B1 (ko) 선택적 안드로겐 수용체 조절제를 이용한 신장 질환, 화상,부상 및 척수 손상의 치료 방법
ES2295009T3 (es) Inhibidores de rho quinasa para la profilaxis y el tratamiento de neumonia intersticial y fibrosis pulmonar.
RU2003101319A (ru) Фармацевтическая композиция, обладающая улучшенным противоопухолевым действием и/или сниженными побочными эффектами, содержащая противоопухолевый агент и производное гидроксамовой кислоты
JP2005511532A5 (enExample)
JP2006523194A5 (enExample)
JP2005519932A5 (enExample)
JP2006524662A5 (enExample)
CN101300257A (zh) 烷基取代的N-[4-(4-氨基-1H-咪唑并[4,5-c]喹啉-1-基)丁基]甲磺酰胺类的酰胺和氨基甲酸酯衍生物和方法
RU95122754A (ru) Производные 2,6-диаминопурина и способ их получения, способ производства лекарства, фармацевтический состав и способ лечения
US20090176785A1 (en) Method of treating arthritis
JP2008521916A (ja) 免疫不全障害の治療のために免疫調節化合物を用いる方法及び組成物
RU2000102359A (ru) Фармацевтическая композиция, обладающая улучшенным противораковым действием и/или сниженными побочными эффектами, содержащая противораковый агент и производное гидроксамовой кислоты
JP2006523193A5 (enExample)
JP2005505618A5 (enExample)
JP2005508962A5 (enExample)
KR20080086527A (ko) 아미노이소인돌린 화합물을 사용하여 피부 루푸스를치료하는 방법
JP2004517099A5 (enExample)
JP3162071B2 (ja) サイトカイン阻害剤
JPH1067662A5 (enExample)
JP2004517098A5 (enExample)
BRPI0712938A2 (pt) mÉtodo para modular excrescÊncia de neurito pelo uso de um antagonista de receptor de galanina-3
JPH1087484A5 (enExample)
JP2006510606A (ja) 骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物
JP2003513075A5 (enExample)
RU2491931C2 (ru) Способы лечения тревоги